Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
34 Results for "
Mer tyrosine kinase
" in MedChemExpress (MCE) Product Catalog:
Products (34)
34 Results for "Mer tyrosine kinase" in MCE Product Catalog:
127
127 Publications Verification
Synonyms: STI571; CGP-57148B
Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
6
Research Areas:
Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .
1
Target:
Research Areas:
Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR2, AXL and MER, with IC50s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. Zanzalintinib exhibits anti-tumor activity. Zanzalintinib has the potential for kinase-dependent diseases and conditions research .
1
1 Cited Publications
Target:
Research Areas:
UNC2541 is a potent and Mer tyrosine kinase (MerTK)-specific inhibitor, binds in the MerTK ATP pocket, with an IC50 of 4.4 nM, more selective over Axl, Tyro3 and Flt3. UNC2541 inhibits phosphorylated MerTK (pMerTK; EC50, 510 nM). UNC2541 abolishes the analgesic and anti-inflammatory effects of ozone in vivo and in vitro .
Synonyms: ARRY-067
Target:
Research Areas:
PF-07265807 (ARRY-067) is a kinase inhibitor with primary targets AXL, MERTK, and TYRO3. PF-07265807 acts as an immunomodulator that cross-activates CD8 + T cells by enhancing dendritic cell function. PF-07265807 blocks downstream signal transduction of AXL and MERTK, and inhibits the proliferation and migration of tumor cells with high expression of these two kinases. PF-07265807 is applicable to research related to advanced or metastatic solid tumors, such as colorectal cancer .
Cat. No.: HY-115778
CAS No.: 2011034-35-6
Target:
Research Areas:
UNC3133 is an orally active, limitedly selective MerTK inhibitor with an IC50 of 3.0 nM. UNC3133 inhibits Axl, Tyro3 and Flt3 kinases, with IC50 values of 17 nM, 31 nM and 6.8 nM, respectively. UNC3133 is applicable to the research of inflammatory diseases and cancers .
Cat. No.: HY-162645
CAS No.: 3029897-97-7
Target:
Research Areas:
BPR5K230 is a dual inhibitor for the receptor tyrosine kinase MER and AXL, with IC50 of 4.1 nM and 9.2 nM. BPR5K230 inhibits the proliferation of Ba/F3-MER with IC50 of 5 nM. BPR5K230 exhibits good pharmacokinetic characteristics in mice, exhibits anti-inflammatory and antitumor against 4T1, MDA-MB-231, MC38 and Hepa1?6 in mouse models .
Cat. No.: HY-15463R
CAS No.: 152459-95-5
Synonyms: STI571 (Standard); CGP-57148B (Standard)
Imatinib (Standard) is the analytical standard of Imatinib. This product is intended for research and analytical applications. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
Cat. No.: HY-16961A
CAS No.: 2244864-88-6
Synonyms: MGCD516 malate; MG-516 malate
Research Areas:
Sitravatinib malate (MGCD516 malate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .
Cat. No.: HY-153012
CAS No.: 2394874-60-1
Target:
Research Areas:
Axl/Mer-IN-1 (Compound 1) is an Axl/Mer receptor tyrosine kinase (Axl/Mer RTK) and CSF1R inhibitor with Kds of <0.1 μM .
Cat. No.: HY-15463S3
Synonyms: STI571-13C,d3; CGP-57148B-13C,d3
Cat. No.: HY-162085
CAS No.: 3048409-80-6
Target:
Research Areas:
Axl-IN-17 (compound 13c) is an orally active, selective AXL inhibitor with an IC50 value of 3.2 nM. Axl-IN-17 reveals antitumor efficacy .
Synonyms: STI571-d3 hydrochloride; CGP-57148B-d3 hydrochloride
Target:
Research Areas:
Imatinib Impurity E is the impurity of Imatinib. Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
Cat. No.: HY-P70958
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: MerTK; Mer; Mer Proto-Oncogene, tyrosine kinase; C-Mer Proto-Oncogene tyrosine kinase; Receptor tyrosine kinase MerTK; Receptor Protein-tyrosine kinase; tyrosine-Protein kinase Mer; Uncharacterized Protein MerTK; Proto-Oncogene C-Mer; Mer Receptor Tyrosin
Species:
Human
Source:
HEK293
Cat. No.: HY-P73824
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: MerTK; Mer; Mer Proto-Oncogene, tyrosine kinase; C-Mer Proto-Oncogene tyrosine kinase; Receptor tyrosine kinase MerTK; Receptor Protein-tyrosine kinase; tyrosine-Protein kinase Mer; Uncharacterized Protein MerTK; Proto-Oncogene C-Mer; Mer Receptor Tyrosin
Species:
Human
Source:
HEK293
Cat. No.: HY-P78581
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: MerTK; Mer; Mer Proto-Oncogene, tyrosine kinase; C-Mer Proto-Oncogene tyrosine kinase; Receptor tyrosine kinase MerTK; Receptor Protein-tyrosine kinase; tyrosine-Protein kinase Mer; Uncharacterized Protein MerTK; Proto-Oncogene C-Mer; Mer Receptor Tyrosin
Species:
Cynomolgus
Source:
HEK293
Cat. No.: HY-P73820
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: MerTK; Mer; Mer Proto-Oncogene, tyrosine kinase; C-Mer Proto-Oncogene tyrosine kinase; Receptor tyrosine kinase MerTK; Receptor Protein-tyrosine kinase; tyrosine-Protein kinase Mer; Uncharacterized Protein MerTK; Proto-Oncogene C-Mer; Mer Receptor Tyrosin
Species:
Mouse
Source:
HEK293
Cat. No.: HY-P73822
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: MerTK; Mer; Mer Proto-Oncogene, tyrosine kinase; C-Mer Proto-Oncogene tyrosine kinase; Receptor tyrosine kinase MerTK; Receptor Protein-tyrosine kinase; tyrosine-Protein kinase Mer; Uncharacterized Protein MerTK; Proto-Oncogene C-Mer; Mer Receptor Tyrosin
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P78489
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: MerTK; Mer; Mer Proto-Oncogene, tyrosine kinase; C-Mer Proto-Oncogene tyrosine kinase; Receptor tyrosine kinase MerTK; Receptor Protein-tyrosine kinase; tyrosine-Protein kinase Mer; Uncharacterized Protein MerTK; Proto-Oncogene C-Mer; Mer Receptor Tyrosin
Species:
Human
Source:
HEK293
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
